What Cellular Technology does

Cellular Technology Limited (CTL) is a US-based life-sciences tools and contract laboratory company founded in 1998/1999 in Ohio, operating under the ImmunoSpot brand. The company specializes in standardized immune monitoring using ELISPOT and FluoroSpot assay technologies, which detect and enumerate antigen-specific T cells and B cells at single-cell resolution for vaccine development, immune-oncology, cell therapy, and translational research applications. Its integrated stack spans high-throughput S6-series analyzers (supporting 1-12 color fluorescence, plus bright-field and colony-counting modalities), proprietary software suites (ImmunoSpot, BioSpot, Fluoro-X) with AI-based IntelliCount and statistics-based SmartCount algorithms, a catalog of standardized kits, serum-free media, cryopreserved characterized PBMC controls, and IQ/OQ plus 21 CFR Part 11 regulatory compliance packages for GxP environments.

CTL monetizes through four streams: (1) one-time enterprise hardware sales of ImmunoSpot and BioSnap analyzers (quote-based, with optional multi-year service contracts), (2) recurring consumable revenue from T cell and B cell kits, detection antibodies, and serum-free media, (3) CRO services spanning whole-blood processing, ELISPOT testing, ELISA, neutralizing antibody assays, flow cytometry, and assay standardization, and (4) sales of cryopreserved characterized PBMC reference samples. Customers are primarily pharmaceutical and biotech companies (vaccine and cell therapy sponsors), academic research institutions, and contract research organizations requiring validated, regulatory-compliant immune monitoring. Approximately 1,000 analyzers operate in regulated environments and thousands have been sold globally.

In April 2026 CTL was acquired by VION Biosciences, becoming a wholly-owned subsidiary while retaining its leadership and ImmunoSpot brand. The company is recognized alongside Mabtech and Oxford Immunotec Global as a dominant player in the ELISPOT and FluoroSpot assay market.

Name

Cellular Technology

Legal name

Cellular Technology Limited

Website

https://immunospot.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

Cellular Technology Limited (CTL) is an Ohio-based life-sciences tools and CRO company that sells ELISPOT/FluoroSpot analyzers, kits, software, and contract testing services for standardized immune monitoring. It serves pharmaceutical and biotech sponsors, academic researchers, and CROs running vaccine, immune-oncology, and cell therapy studies.

Ownership category

akta.pro rank

Product category

Laboratory Analytical Instruments

NAICS

Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

Keywords

• Immune monitoring assays
• ELISPOT analyzers
• FluoroSpot readers
• Cryopreserved PBMC
• Contract research services

Headquarters

HQ city

Cuyahoga Falls

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. ImmunoSpot Analyzers: Sale of ELISPOT/FluoroSpot reader instruments including S6 series analyzers, BioSnap analyzers, and automation accessories (ImmunoBot, ImmunoStack). Revenue from initial hardware purchase with optional service contracts.
2. ELISPOT/FluoroSpot Kits and Reagents: Consumable kit sales including T Cell Kits, B Cell Kits, detection antibodies, enzymatic and fluorescent reagents, serum-free media, and control reagents. Recurring revenue from consumable purchases.
3. CRO Services: Contract research organization services including T Cell/B Cell ELISPOT testing, ELISA, neutralization antibody assays, flow cytometry, sample management, assay standardization, and kit scanning/analysis services.
4. Cryopreserved PBMC: Sale of characterized peripheral blood mononuclear cells including HLA-typed, antigen-specified reactivity, NK-activity characterized, and SARS-CoV-2 characterized samples.
5. Service Contracts and Support: Ongoing service contracts, customer support, training, and consultation services for instrument users.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

CTL designs, manufactures, and sells automated ELISpot and FluoroSpot analyzers (S6 Series, BioSnap) along with ImmunoSpot-branded analysis software, single-color and dual-color T cell and B cell kits, serum-free media, cryopreserved PBMC (ePBMC), and monocyte activation test (MAT) kits. It complements these products with a GLP/GCP-compliant contract laboratory in Shaker Heights, Ohio that runs immune monitoring and immunogenicity assays on a fee-for-service basis for vaccine and immunotherapy developers.

Differentiator

Problem solved

Functional benefit

Brands

• ImmunoSpot®: The company's primary brand platform for ELISPOT and FluoroSpot immune monitoring technology, including analyzers, kits, software, and services.
• BioSpot™
• ImmunoBot™
• ImmunoStack™

Products and services

• S6 Series Analyzers Automated ELISpot and FluoroSpot analyzers that read single-color and dual-color T cell and B cell immune monitoring assays at high throughput, designed for pharmaceutical, biotech, academic, and government immunology laboratories.
• BioSpot Analyzers Automated ELISpot and FluoroSpot readers offered alongside the S6 Series as part of CTL's immune monitoring instrument portfolio.
• ImmunoSpot Analysis Software ImmunoSpot-branded analysis software powered by the proprietary IntelliCount AI spot-counting algorithm, with SmartCount, AutoGate, Live/Dead gates, and dual-color overlays, available in GLP/GCP/CFR Part 11 compliant configurations for regulated environments.
• Fluoro-X Software Software for CTL's FluoroSpot analyzers that enables multi-color fluorescence spot detection, gating, and analysis.
• TVA Cytotoxicity Suite Software suite for CTL's T cell cytotoxicity workflows, providing automated analysis of tumor-infiltrating lymphocyte and target cell killing assays.
• T Cell ImmunoSpot Kits ELISpot kits for detecting antigen-specific T cell responses across human, non-human primate, mouse, rat, and pig species, used with CTL analyzers and ImmunoSpot software.
• B Cell ImmunoSpot Kits ELISpot kits for detecting antigen-specific antibody-secreting B cell responses across human, mouse, pig, and ferret species, used with CTL analyzers and ImmunoSpot software.
• CTL-Test Serum-Free Media Serum-free cell culture media (CTL-Test and CTL-Test PLUS) for immune cell culture in ELISpot, FluoroSpot, and related immune monitoring assays.
• Cryopreserved PBMC (ePBMC) Cryopreserved peripheral blood mononuclear cells (ePBMC) supplied by CTL as standardized positive-control and reference materials for immune monitoring assays.
• Monocyte Activation Test (MAT) Kits In vitro monocyte activation test (MAT) kits for pyrogen and endotoxin testing in pharmaceutical and vaccine quality control release workflows.
• Immune Monitoring CRO Services GLP/GCP-compliant contract laboratory services for ELISpot, FluoroSpot, and immunogenicity assays, delivered from CTL's Shaker Heights, Ohio facility for pharmaceutical, biotech, and academic sponsors.
• Positive Controls (CEF, CPI) Positive control peptide pools (e.g., CEF, CPI) used as standardized reference reagents in T cell ELISpot immune monitoring assays.

Quantifiable outcome

• Detects antigen-specific immune responses as low as 1 in 1,000,000 cells (0.0001% frequency)
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Partnerships

One partnership is on record.

• VION BiosciencescoreStrategic or Co-development Partner · 9 April 2026VION Biosciences completed acquisition of Cellular Technology Limited (CTL) in April 2026. The acquisition adds CTL's ELISPOT and FluoroSpot analyzers, regulatory-grade software, matched consumables, and assay services to VION's portfolio, strengthening its position in immune medicine workflow-critical measurement capabilities including vaccine development, immune-oncology, and cell therapy applications. CTL continues operating under existing leadership while benefiting from VION's broader commercial and strategic infrastructure.

Scale indicators7 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Mabtech: Mabtech is a Swedish specialist in ELISPOT and FluoroSpot reagents, kits, and readers and is explicitly named alongside CTL as one of three dominant players in the 2026–2031 ELISpot/FluoroSpot market report. It is the closest direct peer, competing head-to-head with CTL on kits, analyzers, and PBMC reagents.
• Oxford Immunotec (Revvity): Oxford Immunotec — now part of Revvity — developed the T-SPOT.TB tuberculosis test on ELISPOT technology and is named as the third dominant player in the ELISpot/FluoroSpot market. It competes with CTL in regulated immune monitoring applications and benefits from Revvity's substantially larger commercial reach.

Broad incumbents

• Meso Scale Diagnostics (MSD): MSD operates a broad electrochemiluminescence-based immunoassay platform used across pharma, biotech, and academic immune monitoring. It overlaps with CTL in immunoassay-based biomarker measurement but serves a wider portfolio of targets beyond T/B cell ELISPOT/FluoroSpot.
• Bio-Techne: Bio-Techne (R&D Systems, ProteinSimple, ExoDx) supplies ELISA kits, antibodies, proteins, and reagents used in immune monitoring workflows. It competes with CTL's kits and reagents business and serves overlapping academic and pharma customers, though across a much broader life sciences catalog.
• Luminex (DiaSorin): Luminex, now part of DiaSorin, provides multiplexed bead-based assay systems (xMAP) widely used in immune monitoring and clinical research. It overlaps with CTL's high-throughput, multi-analyte positioning but operates a broader multiplexed instrument and assay portfolio.
• Becton Dickinson (BD Biosciences): BD Biosciences is a global leader in flow cytometry instruments and reagents — directly overlapping with CTL's flow cytometry testing services and broader immune monitoring workflows. It is a much larger incumbent serving the same pharma/biotech and academic customer base.
• Charles River Laboratories: Charles River is a global CRO providing safety assessment, immunology, and cell therapy services to pharma and biotech. It competes with CTL's CRO services arm in immune monitoring, assay standardization, and biologics safety testing (including pyrogen/MAT services).
• Thermo Fisher Scientific: Thermo Fisher operates the broadest life sciences and lab instruments portfolio (including Gibco media, Invitrogen reagents, and CRO services via PPD). It is an indirect peer through overlapping reagents, media, immunoassay kits, and clinical research services used by CTL's customers.
• Beckman Coulter Life Sciences (Danaher): Beckman Coulter, a Danaher operating company, manufactures analytical laboratory instruments and reagents including flow cytometry and immunoassay analyzers. It competes with CTL in regulated lab instrumentation and reagent workflows at a much larger scale and broader portfolio.

Emerging players

• Cellero (subsidiary of Astarte Biologics): Cellero/Astarte Biologics supplies cryopreserved PBMC and characterized immune cell products to immune monitoring researchers, directly competing with CTL's ePBMC product line. It is a smaller, more focused player in the PBMC supply segment of the immune monitoring value chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cellular-technology-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellular Technology